MidCap Financial

Urgently is a digital roadside assistance platform that features a roadside assistance industry to the benefit of global brands, roadside assistance professionals, and consumers. Its solution delivers the quickest, safest, and most innovative roadside assistance service, products and technology by combining location-based services, real-time data, AI, and machine-to-machine communication.

Arq is an environmental technology company that focuses on transforming mining waste into high-value advanced carbon products. By leveraging innovative technologies, Arq aims to contribute to a cleaner and safer world while actively reducing its environmental footprint. The company's operations emphasize sustainability and resource recovery, positioning it as a key player in the oil and energy sector. Through its commitment to environmental responsibility, Arq strives to create solutions that not only enhance the value of mining byproducts but also promote a more sustainable future.

Regis Corporation is a prominent owner, operator, and franchisor of hairstyling and hair care salons, headquartered in Minneapolis, Minnesota. The company operates in the United States, the United Kingdom, Canada, and Puerto Rico, managing over 8,600 salons across various brands, including SmartStyle, Supercuts, Cost Cutters, Roosters, and First Choice Haircutters. Regis provides a range of services such as haircutting, styling, hair coloring, and other beauty treatments, along with the sale of hair care products. In addition to salon services, the company offers digital solutions like OpenSalon Pro, a cloud-based salon management system, and mobile applications for booking and check-in services. Founded in 1922, Regis also operates accredited cosmetology schools and employs more than 41,000 individuals worldwide.

Xtant Medical is a medical technology company that specializes in the design, development, and commercialization of regenerative medicine products and medical devices, particularly in the orthopedic and neurosurgery markets. The company offers a comprehensive portfolio of orthobiologics and spinal implant systems designed to facilitate spinal fusion in complex procedures. Its product lineup includes biomaterials such as OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and 3Demin products, along with various allografts. Xtant Medical primarily serves orthopedic spine surgeons and neurosurgeons treating a range of spinal disorders across different anatomical regions. With a strong presence in the United States, the company has a large field sales force and numerous national and regional contracts, enhancing its competitive position in the spine surgery marketplace. The merger of Bacterin International and X-spine Systems has further strengthened Xtant Medical's product offerings and market reach, promoting growth and innovation in the field.

OrthoPediatrics is a specialized medical device company focused on developing and manufacturing orthopedic implants and instruments specifically for pediatric orthopedic surgeons. The company is dedicated to enhancing the treatment of children's orthopedic conditions through the invention and distribution of innovative, anatomically appropriate implants and unique instrumentation. Its product offerings include various solutions such as PediLoc, PediPlates, Cannulated Screws, and specialized nails for pediatric use. OrthoPediatrics emphasizes the importance of creating devices that cater to the unique anatomical needs of small stature patients, ensuring both safety and efficacy in surgical procedures. The company's commitment to improving surgical experiences is exemplified by its QCR technology, which operates with minimal noise and vibration, thereby reducing patient anxiety during treatments.

Express Wash Concepts operates a chain of car washing facilities dedicated to delivering exceptional customer service and high-quality vehicle cleaning experiences. The company focuses on providing comprehensive maintenance and cleaning services for vehicle owners, specializing in car washing and vacuum cleaning. By prioritizing customer satisfaction, Express Wash Concepts aims to create a reliable and efficient environment for customers to care for their vehicles.

STRATA Skin Sciences, Inc. is a medical technology company focused on developing, commercializing, and marketing products for the treatment of dermatologic conditions. Founded in 1989 and based in Horsham, Pennsylvania, the company operates primarily in two segments: Dermatology Recurring Procedures and Dermatology Procedures Equipment. Its key products include the XTRAC excimer laser and VTRAC lamp systems, which are used to treat a variety of skin disorders such as psoriasis, vitiligo, atopic dermatitis, and eczema. Additionally, STRATA offers the MelaFind system, designed to aid in the identification and management of melanoma skin cancer. The company distributes its products both domestically, directly to physicians, and internationally through distributors.

Marco is a tech-enabled, trade finance platform that provides reliable access to working capital for Latin American SMEs. It promotes paperless processes and dedicated support from industry experts to create a seamless financing solution. The company was founded in 2019 by Jacob Shoihet and Peter D. Spradling and is headquartered in Miami, Florida.

Apyx Medical Corp is a medical device company focused on energy technology, dedicated to developing, manufacturing, and marketing a variety of surgical and cosmetic products. The company is known for its innovative Renuvion cosmetic technology, which enables plastic and cosmetic surgeons to apply controlled heat to tissues, achieving desired aesthetic results with minimal invasiveness. Apyx Medical's flagship J-Plasma system utilizes a patented helium ionization process to generate a stable, focused beam of plasma, allowing for precise cutting, coagulation, and ablation of soft tissue while minimizing unintended damage to surrounding areas. Apyx Medical’s products are utilized in a range of settings, including doctor's offices, surgery centers, and hospitals, highlighting the company's commitment to enhancing surgical outcomes through advanced medical technologies.

ViewRay, Inc. is a company that designs, manufactures, and markets advanced radiation therapy systems for cancer treatment. Its primary product, MRIdian, is an MRI-guided radiation therapy system that allows for simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology, radiation delivery, and proprietary software to accurately locate and track soft-tissue tumors, enabling precise targeting while minimizing radiation exposure to surrounding healthy tissues. By providing real-time imaging during treatment, MRIdian addresses significant limitations of traditional radiation therapy methods, enhancing the safety and effectiveness of cancer treatment. ViewRay serves a diverse clientele, including university hospitals, community hospitals, private practices, government institutions, and independent cancer centers, primarily in the United States and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

Surmodics is a healthcare company specializing in surface modification and in vitro diagnostic technologies. It aims to enhance disease treatment and detection through innovative solutions that address complex medical device and diagnostic challenges. The company operates in two main segments: the medical device unit, which focuses on developing differentiated vascular intervention devices and performance coatings, and the in vitro diagnostics unit, which manufactures chemical and biological components for immunoassays and molecular tests used in diagnostic and biomedical research. Surmodics leverages its expertise in proprietary surface modification and drug-delivery coating technologies alongside its capabilities in device design, development, and manufacturing to meet demanding clinical requirements and support the healthcare industry.

Carbon6 provides a comprehensive suite of software tools designed to enhance the performance of eCommerce businesses on Amazon. The platform offers solutions for listing optimization, profit recovery, PPC management, and inventory control, enabling sellers to drive revenue and operate efficiently. Carbon6 aims to support brand owners and operators in achieving their business goals through innovative technology and data-driven insights.

Carbon6 provides a comprehensive suite of software tools designed to enhance the performance of eCommerce businesses on Amazon. The platform offers solutions for listing optimization, profit recovery, PPC management, and inventory control, enabling sellers to drive revenue and operate efficiently. Carbon6 aims to support brand owners and operators in achieving their business goals through innovative technology and data-driven insights.

TELA Bio, Inc. is a medical technology company based in Malvern, Pennsylvania, established in 2012. The company specializes in the design, development, and marketing of tissue reinforcement materials aimed at addressing unmet needs in soft tissue reconstruction. TELA Bio offers a range of products, including the OviTex Reinforced Tissue Matrix, which is utilized in hernia repair and abdominal wall reconstruction, and the OviTex PRS Reinforced Tissue Matrix, designed for plastic and reconstructive surgery. Additionally, TELA Bio provides OviTex products specifically for laparoscopic and robotic-assisted surgical procedures, which are derived from ovine rumen and incorporate polypropylene fiber. The company's marketing efforts are primarily focused in the United States, utilizing a direct sales force to promote its innovative solutions in soft tissue repair.

Forge Biologics, Inc. is a contract development and manufacturing organization based in Columbus, Ohio, focused on developing and manufacturing gene therapies and genetic medicines. The company specializes in viral vector gene therapies aimed at treating genetic diseases, including a novel approach combining adeno-associated virus (AAV) with umbilical cord transplants for infantile Krabbe disease, a severe neurodegenerative condition. Founded in 2019, Forge Biologics partners with scientists, healthcare professionals, and biotech and pharmaceutical companies to facilitate the transition of gene therapy programs from preclinical development to clinical and commercial-scale production. By providing end-to-end capabilities, the company aims to accelerate the availability of transformative medicines for patients suffering from rare genetic disorders.

Aterian is a technology-enabled consumer product platform that specializes in creating, acquiring, and partnering with brands to develop top-selling consumer products. Founded in 2014, the company leverages proprietary software and an agile supply chain to optimize its operations. Aterian's diverse product portfolio includes home and kitchen appliances, kitchenware, environmental appliances, beauty products, and consumer electronics. The company operates several owned brands, such as Vremi, Healing Solutions, Xtava, TRUWEO, Spiralize, Pohl+Schmitt, and RIF6. With a global presence that includes offices in America, Canada, Poland, Israel, China, and the Philippines, as well as remote employees in France, Australia, and Croatia, Aterian primarily generates revenue through online sales of its consumer products.

UpStack is a company that specializes in providing customized cloud infrastructure solutions through its innovative SaaS-based colocation procurement platform. The platform aids businesses in making informed decisions by utilizing pricing normalization technology, which equalizes pricing across various data center vendors. This approach eliminates guesswork and errors, allowing IT professionals, systems integrators, and consultants to efficiently discover, price, and procure colocation services. By streamlining the procurement process, UpStack significantly reduces both the time and costs typically associated with traditional methods, making it easier for businesses of all sizes to navigate their infrastructure challenges.

Unchained Labs is a life sciences tools company based in Pleasanton, California, specializing in solutions for biologics and gene therapy researchers. Established in 2014, it develops a range of products designed to enhance the efficiency and effectiveness of research in protein stability and formulation. Key offerings include the Optim platform, which allows researchers to measure multiple protein stability parameters simultaneously, and GRUNT, an automated system for biologic formulation preparation. In addition to these, the company provides various tools such as protein sizing systems, stability quantifiers, and automated buffer exchange systems. Unchained Labs serves biopharma and academic customers globally, distributing its products through partnerships in Europe, North and South America, Japan, and other Asian markets.

Modern Campus is a software company specializing in student lifecycle management solutions tailored for higher education institutions. Its SaaS platform focuses on managing continuing education and non-degree programs, catering to students outside the traditional full-time degree framework. By enhancing digital engagement, Modern Campus aims to improve the overall student experience, enabling institutions to increase enrollment, streamline administrative processes, and efficiently oversee their educational offerings.

Xtant Medical is a medical technology company that specializes in the design, development, and commercialization of regenerative medicine products and medical devices, particularly in the orthopedic and neurosurgery markets. The company offers a comprehensive portfolio of orthobiologics and spinal implant systems designed to facilitate spinal fusion in complex procedures. Its product lineup includes biomaterials such as OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and 3Demin products, along with various allografts. Xtant Medical primarily serves orthopedic spine surgeons and neurosurgeons treating a range of spinal disorders across different anatomical regions. With a strong presence in the United States, the company has a large field sales force and numerous national and regional contracts, enhancing its competitive position in the spine surgery marketplace. The merger of Bacterin International and X-spine Systems has further strengthened Xtant Medical's product offerings and market reach, promoting growth and innovation in the field.

LendingPoint LLC is a financial technology company established in 2014, headquartered in Kennesaw, Georgia, with additional offices in New York and Nevada. The company specializes in online consumer lending, offering a cloud-based platform that utilizes predictive risk algorithms to provide personal loans for various purposes, including debt consolidation, home improvement, and medical expenses. Additionally, LendingPoint offers financing solutions through its LendingPoint Merchant Solutions platform, catering to merchants, service providers, and medical institutions. The company's innovative lending operating system enhances credit approval processes for e-commerce and point-of-sale purchases while employing advanced fraud prevention and risk management techniques to create diverse financing opportunities across the credit spectrum.

Medexus Pharmaceuticals Inc. is a specialty pharmaceutical company operating in Canada and the United States, dedicated to developing and commercializing treatments for rare and auto-immune diseases. The company's primary products include Rasuvo and Metoject, which are formulations of methotrexate for rheumatoid arthritis and other auto-immune conditions. Additionally, Medexus offers IXINITY, a therapeutic for Hemophilia B, and Rupall, indicated for various allergic conditions. The company's portfolio also features Cuvposa for sialorrhea, Gliolan for brain tumor visualization, and Treosulfan, used in stem cell transplantation preparation. Medexus Pharmaceuticals, based in Verdun, Canada, previously operated as Pediapharm Inc. and has since expanded its focus to include a range of therapeutic areas such as rheumatology, oncology, hematology, allergy, and pediatrics.

Digital Reasoning Systems, Inc. is a developer of an artificial intelligence cognitive computing platform that specializes in processing and organizing unstructured data into meaningful insights for businesses. Founded in 2000 and based in Franklin, Tennessee, with additional offices in New York, Washington, D.C., and London, the company offers its primary product, Synthesys, which utilizes advanced features such as natural language processing, entity resolution, and link analysis. This platform is designed to automatically categorize, link, retrieve, and profile unstructured data, providing critical intelligence and insights for industries including finance, healthcare, and legal sectors. Digital Reasoning's solutions support intelligence analysts in both government and commercial markets, enhancing their ability to visualize connections within data sets and address risks and threats effectively. The company maintains strategic partnerships to enhance its offerings and expand its reach in the market.

Arboretum Investment Advisors, LLC specializes in providing financing and investment advisory services focused on fundamental capital assets that are essential to middle-market companies globally. The firm manages funds that offer asset-backed financing, emphasizing non-correlated, income-producing investment strategies to diversify investor portfolios. In addition to financing, Arboretum is involved in asset management and asset servicing, catering specifically to the needs of its clients in the middle-market sector.

Protagonist Therapeutics is a clinical-stage biopharmaceutical company focused on developing peptide-based product candidates to meet unmet medical needs in hematology and gastroenterology. The company is advancing several key products, including PTG-300, an injectable hepcidin mimetic in Phase II clinical trials for treating beta-thalassemia-related anemia, and PTG-200, an antagonist peptide that has completed Phase I trials aimed at moderate-to-severe Crohn's disease. Additionally, PN-943, an oral integrin antagonist, is in Phase I trials for inflammatory bowel disease. Protagonist also explores both oral and injectable peptide candidates for various gastrointestinal conditions. The company has established a collaboration with Janssen Biotech for the development and commercialization of PTG-200. Founded in 2006, Protagonist Therapeutics is headquartered in Newark, California.

Sight Sciences is a medical device company specializing in ophthalmic devices and glaucoma implants aimed at treating irreversible blindness. Headquartered in Menlo Park, California, the company has developed the OMNI Surgical System, which allows for targeted treatment of glaucoma by addressing three points of resistance with a single device and incision. Additionally, Sight Sciences offers TearCare, a wearable technology that delivers adjustable thermal energy to the meibomian glands to treat conditions like dry eye and meibomian gland dysfunction. The company also provides SmartLid, which aids in the natural expression of meibum when it is in a melted state. Founded in 2010, Sight Sciences focuses on both surgical and non-surgical technologies to address prevalent eye diseases and has a commercial office in Southlake, Texas.

Gossamer Bio is a clinical-stage biopharmaceutical company based in San Diego that specializes in the discovery, development, and commercialization of innovative therapeutic products targeting significant unmet medical needs. Founded by former executives from Receptos, the company focuses on areas such as immunology, inflammation, fibrosis, and oncology. Its pipeline includes several promising candidates: Seralutinib, aimed at addressing pulmonary arterial hypertension; GB004, for inflammatory bowel disease; GB1275, targeting various oncology indications; and GB001, designed for moderate-to-severe eosinophilic asthma. Gossamer Bio's strategy involves leveraging a rich in-licensing environment to enhance its therapeutic offerings, supported by a team recognized for their successful track record in drug development.

Organogenesis Holdings Inc. is a regenerative medicine company that specializes in the development, manufacturing, and commercialization of advanced wound care and surgical products primarily in the United States. Its portfolio includes notable advanced wound care products such as Apligraf, which treats venous leg ulcers and diabetic foot ulcers, and Dermagraft for diabetic foot ulcers. Other products include PuraPly AM, designed to manage biofilm in various wound types, and Affinity and NuShield for different wound applications. In surgical and sports medicine, Organogenesis offers products like ReNu for joint and tendon applications and NuCel for bony fusion. The company's pipeline features innovative solutions for treating burns, chronic wounds, and mucogingival conditions, among others. Serving hospitals, wound care centers, and physician offices, the company uses direct sales representatives and independent agencies for distribution. Founded in 1985 and headquartered in Canton, Massachusetts, Organogenesis is recognized for pioneering living cell-based therapies, with Apligraf being the first FDA-approved product of its kind.

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel oral and small-molecule medicines to address rare diseases with significant unmet medical needs. The company's first approved product, RAPIVAB, is an intravenous neuraminidase inhibitor for treating acute uncomplicated influenza, marketed under various names globally. BioCryst has developed ORLADEYO, an oral medication approved for preventing hereditary angioedema attacks in adults and pediatric patients aged 12 and older, and is currently under regulatory review in additional regions. The company is advancing several other product candidates, including BCX9930, an oral Factor D inhibitor for complement-mediated diseases; BCX9250, an ALK-2 inhibitor for fibrodysplasia ossificans progressiva; and Galidesivir, an RNA-dependent RNA polymerase inhibitor aimed at treating various RNA viruses. Founded in 1986 and headquartered in Durham, North Carolina, BioCryst engages in collaborations with various institutions and organizations to enhance its research and development efforts across infectious and inflammatory diseases.

Sonar Entertainment, Inc. is an independent entertainment studio based in Los Angeles, California, with additional offices in Toronto, Miami, London, Sydney, and Singapore. Founded in 1979 and formerly known as RHI Entertainment, the company specializes in the development, production, financing, and distribution of television series, miniseries, and movies for both domestic and international audiences. Sonar offers a diverse range of content across various genres, including action, comedy, drama, horror, and reality. It also distributes a library of titles and sells DVDs and digital media products online. With a commitment to nurturing creative talent, Sonar provides a comprehensive platform that supports the entire production process while ensuring broad access to its content through collaborations with local networks and producers.

Kashable LLC operates an online platform that provides employer-sponsored voluntary benefit programs, focusing on financial wellness for employees. Founded in 2013 and based in New York, the company allows eligible employees to apply for loans online, facilitating access to affordable financing for managing debt or covering unexpected expenses. The platform enables automatic repayment through structured payroll deductions, ensuring a seamless experience for users. By offering socially responsible financing options, Kashable aims to support employees in achieving better financial stability while providing employers with a valuable benefit to enhance their employee assistance programs.

The Credit Junction, LLC is an asset-based lending platform that specializes in providing working capital, growth, and supply chain financing solutions to small and mid-size enterprises in the United States and Canada. Founded in 2014 and headquartered in New York, the company leverages technology and data intelligence alongside traditional asset-based credit metrics to streamline the lending process. It offers asset-based loans of up to $7.5 million, targeting growth-oriented suppliers, distributors, and manufacturers with revenues ranging from $5 million to $50 million. The Credit Junction also operates user-friendly online portals for borrowers and affiliates, allowing for efficient document submission and facilitating a smooth application, vetting, and approval process. The company has formed strategic partnerships with various organizations to enhance its offerings and reach.

ZPower, LLC is a developer and manufacturer of rechargeable silver-zinc micro batteries, primarily serving the hearing aid, medical device, and portable electronics markets. Founded in 1996 and based in Camarillo, California, the company offers a range of products, including various models of rechargeable micro batteries and charging systems for hearing aids. ZPower's advanced battery technology aims to enhance product development for manufacturers and improve performance for end-users, promoting a better user experience and environmental sustainability. The company filed for reorganization under Chapter 11 in March 2020, indicating ongoing challenges in its operations.

Partner Therapeutics, Inc. is an oncology company based in Lexington, Massachusetts, dedicated to the development and commercialization of approved and late-stage cancer therapies. The company focuses on improving treatment outcomes and reducing overall healthcare costs for cancer patients through a comprehensive range of therapies, from primary treatments to supportive care. One of its key products is Leukine, which promotes the growth of white blood cells to aid in cancer treatment. Founded in 2017, Partner Therapeutics aims to connect investigators and healthcare professionals in the field of oncology, ensuring effective treatments are accessible to patients at all stages of their cancer journey.

DNAnexus, Inc. is a provider of cloud-based genome informatics and data management tools aimed at enterprises engaged in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and integration with clinical and phenotypic data, promoting seamless collaboration among users. Key offerings include MOSAIC Microbiome, a platform for collaborative microbiome research; DNAnexus Apollo, which focuses on clinico-genomic data exploration; and DNAnexus Titan, a comprehensive data analysis solution. Additionally, DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration. The Clinico-Genomic Data Solution program addresses the need for disease-specific datasets by building networks with healthcare partners to enhance diagnosis and treatment pathways. DNAnexus serves a diverse client base, including biopharmaceutical companies, genome centers, and diagnostic test providers, and has established a strategic alliance with WuXi NextCODE Genomics. The company also maintains additional offices in San Francisco, London, and Prague.

Sarepta Therapeutics is a biopharmaceutical company headquartered in Cambridge, Massachusetts, that specializes in the discovery and development of precision genetic medicines targeting rare diseases. Founded in 1980, the company employs innovative approaches such as gene therapy, RNA-targeted exon skipping, and gene editing to create novel treatments. Sarepta focuses on addressing unmet medical needs through its proprietary RNA-targeted technology platforms, which facilitate the rapid development of drug candidates. While the company targets a broad range of diseases, most of its product candidates are currently in the early stages of development. To support its manufacturing needs, Sarepta collaborates with third-party contractors.

Elutia is a commercial-stage regenerative medicine company dedicated to developing innovative products aimed at enhancing patient outcomes during surgical procedures, particularly for those receiving implantable medical devices. The company focuses on several key areas, including Device Protection, Women's Health, and Cardiovascular health, with the Women's Health segment generating the highest revenue. Utilizing proprietary tissue processing platforms, Elutia has created a range of advanced regenerative medical products that closely resemble natural biological materials. These products are designed to address unmet clinical needs by promoting healthy tissue formation and minimizing complications commonly associated with medical device implants, such as scar tissue formation and capsular contraction.

Fundation Group LLC, established in 2011 and headquartered in Reston, Virginia, specializes in developing and providing a digital credit lending platform. This platform connects financial institutions with small businesses, facilitating access to working capital and growth capital. Fundation partners with banks and other institutions, offering outsourced lending and referral programs, along with point-of-sale financing solutions. The company's mission is to empower the small business economy by enabling critical institutions to better serve their small business clients through technology and advanced analytics.

Oxford Immunotec is a diagnostics company specializing in the development and commercialization of proprietary tests for immunology and infectious diseases. Headquartered in the UK, with operations in the US, the company's core technology, T-SPOT, measures specific T cell responses to inform diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. Its flagship product, T-SPOT.TB, detects active and latent tuberculosis infection, while T-SPOT.CMV monitors cytomegalovirus in transplant recipients. Oxford Immunotec serves independent laboratories, hospital systems, and public and private institutions worldwide.

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel oral and small-molecule medicines to address rare diseases with significant unmet medical needs. The company's first approved product, RAPIVAB, is an intravenous neuraminidase inhibitor for treating acute uncomplicated influenza, marketed under various names globally. BioCryst has developed ORLADEYO, an oral medication approved for preventing hereditary angioedema attacks in adults and pediatric patients aged 12 and older, and is currently under regulatory review in additional regions. The company is advancing several other product candidates, including BCX9930, an oral Factor D inhibitor for complement-mediated diseases; BCX9250, an ALK-2 inhibitor for fibrodysplasia ossificans progressiva; and Galidesivir, an RNA-dependent RNA polymerase inhibitor aimed at treating various RNA viruses. Founded in 1986 and headquartered in Durham, North Carolina, BioCryst engages in collaborations with various institutions and organizations to enhance its research and development efforts across infectious and inflammatory diseases.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions requiring long-term treatment. The company is known for its innovative drug delivery platform, DUROS, which stabilizes and administers therapeutic proteins and peptides effectively. Among its key products is ITCA 650, currently in phase 3 clinical trials for type 2 diabetes, designed to provide patients with continuous dosing of an incretin mimetic therapy. Intarcia also explores treatments for obesity and other chronic disorders. Established in 1995 and headquartered in Boston, Massachusetts, Intarcia operates a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina. The company was previously known as BioMedicines, Inc. before adopting its current name in 2004.

IOU Financial Inc., through its subsidiary IOU Central Inc., operates a commercial lending business in North America, specializing in providing capital to small businesses across various sectors including medical and dental practices, retail stores, restaurants, and manufacturing companies. Founded in 1977 and headquartered in Montreal, Canada, the company has funded over $200 million in small business loans, showcasing its extensive experience in the field. IOU Financial originates and services commercial loans, retaining a portfolio of loans receivable while also selling loans to third-party purchasers on a non-recourse basis. This approach allows the company to offer flexible lending solutions tailored to the growth opportunities of its diverse clientele.

Spectra7 Microsystems Inc. is an analog semiconductor company based in San Jose, California, with operations in Canada and China. The company focuses on providing high-performance solutions that enhance bandwidth, speed, and resolution for consumer electronics. Its product offerings include advanced technologies for virtual reality (VR) and augmented reality (AR), such as the VR7050, which supports lightweight interconnects for gesture recognition, and the AR-Connect, an integrated solution for AR vision systems. Additionally, Spectra7 develops high-bandwidth, low-latency products like DreamWeVR for VR headsets and AR glasses. The company also caters to data center needs with specialized interconnects and consumer interfaces like GaugeChanger and USB 3.1, suitable for ultra-thin laptops, tablets, and mobile devices. Through its innovations, Spectra7 Microsystems aims to facilitate disruptive designs in various connectivity markets.

The Spectranetics Corporation specializes in the development, manufacturing, and distribution of single-use medical devices for minimally invasive cardiovascular procedures. Its portfolio includes laser and aspiration catheters, scoring balloon catheters, and drug-coated balloon catheters, used to cross, prepare, and treat arterial blockages in the legs and heart. Additionally, the company offers products for the removal of pacemaker and defibrillator cardiac leads, and provides laser systems for various cardiovascular procedures. Spectranetics sells its products directly and through distributors worldwide, with a focus on innovation to meet the demands of complex cardiac lead removal and vascular intervention procedures. Headquartered in Colorado Springs, Colorado, the company operates as a subsidiary of Philips Holding USA Inc.

Flexion Therapeutics, Inc. is a biopharmaceutical company based in Burlington, Massachusetts, that specializes in the discovery, development, and commercialization of therapies for musculoskeletal conditions, particularly osteoarthritis. The company's primary product, ZILRETTA, is an intra-articular injection approved for managing knee pain associated with osteoarthritis in the United States. In addition to ZILRETTA, Flexion is advancing several other innovative treatments, including FX201, a gene therapy aimed at producing an anti-inflammatory protein to alleviate knee pain, and FX301, a NaV1.7 inhibitor designed for post-operative pain management. Founded in 2007, Flexion Therapeutics aims to enhance the effectiveness of local therapies while partnering with other pharmaceutical and biotechnology companies to expand its product offerings and share development risks.

Quotient Biodiagnostics specializes in the development and provision of high-quality immunohematology products for hospitals and blood banks in the United States. The company leverages over 30 years of expertise in research, development, and manufacturing through its wholly-owned subsidiary, Alba Bioscience. Quotient offers a range of transfusion diagnostics products that have been distributed globally, either directly or through partnerships with major transfusion companies. By focusing on the needs of healthcare institutions, Quotient aims to enhance the quality and reliability of blood transfusion practices.

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company headquartered in Raleigh, North Carolina, dedicated to addressing the needs of patients with chronic pain and opioid dependence. Founded in 1997, the company focuses on the development and commercialization of innovative pharmaceutical products, leveraging its proprietary BioErodible MucoAdhesive (BEMA) drug-delivery technology. This technology allows for the creation of small erodible polymer films designed for effective application to the buccal mucosa. BioDelivery Sciences offers a range of products, including BELBUCA, a buprenorphine buccal film for chronic pain management, and BUNAVAIL, a buprenorphine and naloxone buccal film aimed at treating opioid dependence. Additionally, it provides ONSOLIS, a fentanyl buccal soluble film for managing breakthrough pain in cancer patients, and Symproic, which treats opioid-induced constipation in adults with chronic pain. The company's focus on novel drug delivery methods enables it to address important unmet medical needs in pain management and addiction medicine.

Staffing 360 Solutions is a company operating in the international staffing sector, focusing on professional placement and staffing services across various industries. It employs a buy-and-build strategy by acquiring both domestic and international staffing organizations. The company is organized into three business streams: Professional Staffing, Commercial Staffing, and Employer of Record. Staffing 360 Solutions primarily supports sectors such as accounting and finance, information technology, engineering, administration, and commercial disciplines. By integrating acquired firms, the company aims to enhance its service offerings and expand its market presence globally.

Aventine Renewable Energy Holdings is a prominent producer of corn-based fuel-grade ethanol and related by-products. The company specializes in the production and marketing of renewable fuels, which serve as gasoline additives and contribute to reducing dependence on foreign oil. Aventine's facilities focus on generating low carbon renewable fuels, including ethanol and various co-products, which also help offset a substantial portion of corn costs. By supplying these products to major energy and food companies in the United States and globally, Aventine plays a significant role in promoting environmental sustainability and improving automobile performance.

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company based in Bala Cynwyd, Pennsylvania, dedicated to developing treatments for complex rare diseases. Its primary focus is on Friedreich's ataxia, a rare and progressive genetic disorder, for which it is advancing its lead compound, CTI-1601, through a Phase 1 clinical program. CTI-1601 is designed as a recombinant fusion protein that delivers human frataxin, an essential protein, directly to the mitochondria using a novel cell-penetrating peptide technology. In addition to Friedreich's ataxia, Larimar aims to leverage its intracellular delivery platform to create additional fusion proteins targeting other rare diseases associated with deficiencies in bioactive compounds.

Omeros Corporation is a Seattle-based biopharmaceutical company that focuses on discovering, developing, and commercializing small-molecule and protein therapeutics targeting inflammation, complement-mediated diseases, and disorders of the central nervous system. The company offers OMIDRIA, a product used during cataract surgery in the United States. Omeros is advancing several clinical programs, including narsoplimab, which is in Phase III trials for conditions such as hematopoietic stem-cell transplant-associated thrombotic microangiopathy and immunoglobulin A nephropathy, as well as Phase II trials for lupus nephritis. Other key programs include OMS405, targeting opioid and nicotine addiction, and OMS527, aimed at treating addiction and movement disorders. The company's preclinical pipeline includes compounds addressing various conditions, such as paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders. Founded in 1994, Omeros is dedicated to addressing both large-market and orphan indications through innovative therapeutic approaches.

Amicus Therapeutics, Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of therapies for rare and orphan diseases. Founded in 2002 and headquartered in Cranbury, New Jersey, the company focuses on developing innovative treatments, including Galafold, an orally administered pharmacological chaperone for Fabry disease. Amicus is also advancing its pipeline with a Phase 3 clinical study of AT-GAA for Pompe disease. The company's research includes a range of first-in-class small molecules designed to treat lysosomal storage diseases by stabilizing misfolded enzymes in patients. This therapeutic approach potentially enhances the effectiveness of enzyme replacement therapies. Amicus Therapeutics has established collaborations with institutions such as Nationwide Children's Hospital and the University of Pennsylvania to further its research and development efforts.

Apollo Endosurgery, Inc. is a medical technology company based in Austin, Texas, specializing in the design, development, and commercialization of innovative medical devices for gastrointestinal health. Founded in 2005, the company focuses on advancing therapeutic endoscopy as a less invasive alternative to traditional surgical procedures, thereby reducing complication rates and overall healthcare costs. Its product portfolio includes the OverStitch and OverStitch Sx Endoscopic Suturing Systems, which enable physicians to place full-thickness sutures and secure tissue approximation through flexible endoscopy. Additionally, Apollo offers the X-Tack Endoscopic HeliX Tacking System and the Orbera Intragastric Balloon, which aids in weight management by reducing stomach capacity. The company's devices cater to gastroenterologists and bariatric surgeons, addressing various gastrointestinal conditions such as acute perforations and chronic fistulas. Apollo Endosurgery's commitment to innovation is rooted in the collaborative efforts of a distinguished group of gastroenterologists and surgeons who aimed to enhance the field of therapeutic endoscopy.

Quotient Biodiagnostics specializes in the development and provision of high-quality immunohematology products for hospitals and blood banks in the United States. The company leverages over 30 years of expertise in research, development, and manufacturing through its wholly-owned subsidiary, Alba Bioscience. Quotient offers a range of transfusion diagnostics products that have been distributed globally, either directly or through partnerships with major transfusion companies. By focusing on the needs of healthcare institutions, Quotient aims to enhance the quality and reliability of blood transfusion practices.

Theraclone Sciences, Inc. is a Seattle-based discovery-stage biotechnology company focused on developing novel therapeutic antibodies for the treatment of cancer and infectious diseases. The company utilizes its In-Situ Therapeutic Antibody Rescue technology to rapidly test human antibodies, identifying those with exceptional biological functions. Notable among its offerings is TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza. Theraclone’s antibody programs are in varying stages of preclinical and clinical development, targeting significant unmet medical needs such as triple negative and endocrine treatment-resistant HER-2 negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Theraclone was founded in 2004 and was formerly known as Spaltudaq Corporation, changing its name in March 2009. The company is privately held and has received venture funding from several investment firms.

Stellar Pharmaceuticals Inc. is an innovative Canadian Health Care Company focused on providing healthcare professionals and their patients.

Endocyte, Inc. is a biopharmaceutical company focused on developing receptor-targeted therapies for cancer and inflammatory diseases. Headquartered in West Lafayette, Indiana, the company creates innovative small molecule drug conjugates (SMDCs) and companion imaging agents. Among its key products, Vintafolide is in Phase IIb clinical trials for non-small cell lung cancer, while EC1456 and EC1169 are in Phase I trials for advanced solid tumors and metastatic castration-resistant prostate cancer, respectively. Additionally, Endocyte is developing several pre-clinical candidates, including EC2629 for cancer treatment and EC2319 for inflammatory diseases. The company has established collaborations with Purdue Research Foundation and other organizations to advance its pipeline. Founded in 1995, Endocyte operates as a subsidiary of Novartis AG.

Kashable LLC operates an online platform that provides employer-sponsored voluntary benefit programs, focusing on financial wellness for employees. Founded in 2013 and based in New York, the company allows eligible employees to apply for loans online, facilitating access to affordable financing for managing debt or covering unexpected expenses. The platform enables automatic repayment through structured payroll deductions, ensuring a seamless experience for users. By offering socially responsible financing options, Kashable aims to support employees in achieving better financial stability while providing employers with a valuable benefit to enhance their employee assistance programs.